Heart failure & cardiomyopathies
Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial
Authors' conclusion
We found no evidence that the effects of FDI on heart failure hospitalisations, cardiovascular death, haemoglobin and quality of life differed by age. These findings support its use in patients with HFrEF and iron deficiency, including older adults.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiencyrandomised patients (median age 73 years)
- Participants
- 1,137 patients
- Comparison
- Ferric derisomaltose (FDI) versus usual care in each age subgroup
- Primary endpoint
- Composite of:
- Recurrent heart failure hospitalisations
- Cardiovascular death
Methodological detailsprespecified analysis, stratified into four quarters by age group
- Prespecified analysis
- Stratified into four quarters by age group
Primary result
As reported in the abstract
FDI vs usual careRate ratio (95% CI)
<67 years
0.87(0.61–1.23)
67-73 years
0.93(0.66–1.32)
74-79 years
0.88(0.59–1.33)
>79 years
0.66(0.45–0.96)
Secondary outcomes
Improvements in haemoglobin and quality of life scores across age groups · 4 months
- Did not differ statistically across age groups
- p-interaction=0.92 (haemoglobin)
- p-interaction=0.64 (quality of life)
Baseline characteristics by age
- Older patients were more symptomatic, with higher N-terminal-pro B-type natriuretic peptide levels and poorer renal function
Original publication
Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial. Heart. Published 12 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →